Industry News

Teva Reaches Settlement in ProAir� HFA Patent Case Teva Pharmaceutical Industries Ltd.
BioMarin Announces Health Canada Approval of VIMIZIM� (elosulfase alfa) for the Treatment of Morquio A Syndrome
FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq� (belinostat) for Injection
NAFDAC Clamps Down on Manufacturers of Antibiotics, Anti-Malarials Without Mobile Authentication
Dallen Medical Secures FDA Clearance for Disposable Compressyn Staple Delivery System for Small Bone Fixation
Merz to Acquire Ulthera
Scrutiny of chemical triclosan could lead to FDA rules by 2018
United States : ANI PHARMA declares acquisition of Lithobid tablets from NOVEN THERAPEUTICS
Medtronic Announces Class I Recall Of Duet Neuro Drainage And Monitoring Systems
NaturaLyte Manufacturer Issues Recall, Citing Unacceptable Bacterial Infection Risk, Reports Baron and Budd
SUN PHARMA RECALLS 200 VIALS OF CANCER DRUG, SAYS USFDA
Flamel Technologies Announces FDA Approval of VAZCULEP
NutriGold's Fish Oil Supplement IFOS 5-star Certified and ConsumerLab Approved
Teva Reaches Settlement in ProAir HFA Patent Case
Ruvo Center: We are not meeting the challenge of curing Alzheimer's disease
Pharma companies on a talent hunt to fill skills gap [India Business]
FDA Classifies ConvaTec's Voluntary Global Recall of Flexi-Seal Control Fecal Management System (FMS) as Class I
St. Jude Medical Resolves FDA Warning Letter for Sylmar Facility
FDA Approves Updated Labeling for Gattex� (Teduglutide [rDNA origin]) for Injection to Include Long-Term Data
NutriGold's Fish Oil Supplement IFOS 5-star Certified and ConsumerLab Approved
Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE� Antibody Blinatumomab In Acute Lymphoblastic Leukemia Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer
Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE Antibody Blinatumomab In Acute Lymphoblastic Leukemia Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer
Glaxo And Theravance Submits Supplemental NDA For Breo Ellipta
Glaxo and Theravance Submit Supplemental NDA For Breo Ellipta
FSC Laboratories, Inc. to Market AcipHex Sprinkle (rabeprazole sodium) in the U.S.